# InterCure Ltd. (INCR)

> Source: Nexqual · https://nexqual.com/INCR · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, InterCure Ltd. (INCR), nexqual.com/INCR" · informational, not investment advice.

**Price:** USD 4.65 (-1.27% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 4.71 · day 4.65–4.94 · 52w 3.4–7.95 · market cap $69.8M · NGM

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -39.6% vs S&P 500 +18.1%; 5Y -86.9% vs S&P 500 +85.1%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -39.6% | -86.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -39.7% | -33.3% |
| Volatility (annualized) | 65.7% | 63.4% |
| Max drawdown | -54.1% (Oct 2025→Mar 2026) | -91.2% (Nov 2021→Mar 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.31 +7.13% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24%

## More
Full page: https://nexqual.com/INCR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt